More recently, ROS-1 rearrangements have been identified as oncogenic drivers, affecting 1–2% of NSCLC patients, with similar clinicopathologic characteristics to ALK-positive patients [39]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.